AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
Trump’s pharmaceutical tariffs could affect some drugmakers more than others
Related Posts
The euro zone is ready for a new member: Bulgaria
Bulgaria’s ascension to the euro would take the bloc to 21 members.
Top 7 Graph Database Visualization Tools
Data visualization is a powerful technique that transforms complex data into easily understandable visual representations. Let us explore how data…
Gazans anxiously await ceasefire, fearing last-minute catastrophes
Civilians in Gaza nervously await a ceasefire after 15 relentless months of war.